Eflornithine is a cost‐effective alternative to melarsoprol for the treatment of second‐stage human West African trypanosomiasis in Caxito, Angola
Authors:
- 26 February 2008
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 13 (2) , 265-271
Abstract
Summary: Objective To compare the cost‐effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis.Method We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost‐effectiveness analysis, comparing the efficiency of an eflornithine‐based approach with melarsoprol. Endpoints calculated were: cost per death avoided; incremental cost per additional life saved; cost per years of life lost (YLL) averted; incremental cost per YLL averted. Sensitivity analysis was done for all parameters for which uncertainty existed over the plausible range. We did an analysis with and without cost of trypanocidal drugs included.Results Effectiveness was 95.6% for melarsoprol and 98.7% for eflornithine. Cost/patient was 504.6 for melarsoprol and 552.3 for eflornithine, cost per life saved was 527.5 USD for melarsoprol and 559.8 USD for eflornithine without cost of trypanocidal drugs but it increases to 600.4 USD and 844.6 USD per patient saved and 627.6 USD and 856.1 USD per life saved when cost of trypanocidal drugs are included. Incremental cost‐effectiveness ratio is 1596 USD per additional life saved and 58 USD per additional life year saved in the baseline scenario without cost of trypanocidal drugs but it increases to 8169 USD per additional life saved and 299 USD per additional life year saved if costs of trypanocidal drugs are included.Conclusion Eflornithine saves more lives than melarsoprol, but melarsoprol is slightly more cost‐effective. Switching from melarsoprol to eflornithine can be considered as a cost‐effective option according to the WHO choice criteria.Keywords
This publication has 19 references indexed in Scilit:
- Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of CongoTropical Medicine & International Health, 2007
- Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'IvoireNew England Journal of Medicine, 2006
- Evaluation of current strategies and future priorities for improving health in developing countriesBMJ, 2005
- Cost effectiveness analysis of strategies for maternal and neonatal health in developing countriesBMJ, 2005
- Cost effectiveness analysis of strategies for child health in developing countriesBMJ, 2005
- Trypanosomiasis Control, Democratic Republic of Congo, 1993–2003Emerging Infectious Diseases, 2005
- Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African TrypanosomiasisClinical Infectious Diseases, 2005
- Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease riskThe Lancet, 2003
- Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trialThe Lancet, 2000
- Cost‐effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in UgandaHealth Economics, 1995